Neurovascular Coupling Restoration Therapy

📖 Wiki Page

idea616 wordssynced 2026-04-02

Overview

flowchart TD ideas_payload_neurovascular_co["Neurovascular Coupling Restoration Therapy"] ideas_payload_neurovascular_co["concept"] ideas_payload_neurovascular_co -->|"related to"| ideas_payload_neurovascular_co style ideas_payload_neurovascular_co fill:#81c784,stroke:#333,color:#000 ideas_payload_neurovascular_co["targets"] ideas_payload_neurovascular_co -->|"related to"| ideas_payload_neurovascular_co style ideas_payload_neurovascular_co fill:#81c784,stroke:#333,color:#000 ideas_payload_neurovascular_co["dysfunction"] ideas_payload_neurovascular_co -->|"related to"| ideas_payload_neurovascular_co style ideas_payload_neurovascular_co fill:#81c784,stroke:#333,color:#000 ideas_payload_neurovascular_co["precedes"] ideas_payload_neurovascular_co -->|"related to"| ideas_payload_neurovascular_co style ideas_payload_neurovascular_co fill:#81c784,stroke:#333,color:#000 style ideas_payload_neurovascular_co fill:#4fc3f7,stroke:#333,color:#000

This therapeutic concept targets the neurovascular coupling (NVC) dysfunction that precedes and exacerbates cognitive decline in Alzheimer's disease and other neurodegenerative disorders. Neurovascular coupling refers to the precise coordination between neuronal activity and cerebral blood flow - when neurons fire, nearby blood vessels dilate to deliver increased oxygen and glucose. This coupling is impaired early in AD, contributing to neuronal dysfunction before amyloid or tau pathology becomes widespread["@takano2014"][@oses2023].

Mechanism of Action

...

Overview

Mermaid diagram (expand to render)

Mechanism of Action

Neurovascular Coupling Pathway

The NVC pathway involves:

Neuronal activation - Schaffer collateral stimulation triggers glutamate release

Astrocyte calcium waves - Astrocyte end-feet respond with calcium increases

Arachidonic acid metabolism - Produces vasodilatory prostaglandins and EETs (epoxyeicosatrienoic acids)

Vascular smooth muscle and pericyte relaxation - Causes vessel dilation and increased blood flow

Elevated oxygen and glucose delivery - Meets increased neuronal metabolic demands

Therapeutic Target

In AD and aging, this pathway fails at multiple points:

Dysfunctional astrocyte calcium signaling reduces prostaglandin production
Pericyte constriction limits capillary dilation
Reduced nitric oxide bioavailability impairs vasodilation
Amyloid-beta directly inhibits astrocyte-mediated dilation

The therapy aims to restore NVC by:

Astrocyte calcium sensitizers - Enhance astrocyte signaling

Pericyte relaxants - Target PDGFR-beta and smooth muscle pathways

Nitric oxide donors - Restore vasodilatory capacity

EET analogs - Directly activate vasodilatory pathways

Rubric Scores

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | Addresses early NVC dysfunction before amyloid/tau pathology - novel intervention window |
| Mechanistic Rationale | 9 | Strong evidence NVC impairment precedes clinical symptoms; multiple therapeutic nodes available |
| Addresses Root Cause | 8 | Targets metabolic insufficiency driving neurodegeneration, not just proteinopathy |
| Delivery Feasibility | 7 | Small molecules and biologics can target astrocyte/pericyte pathways |
| Safety Plausibility | 7 | Enhancing physiological blood flow has safety precedent |
| Combinability | 9 | Compatible with anti-amyloid, metabolic, and vascular therapies |
| Biomarker Availability | 8 | fMRI, ASL, and CBF measurements can track NVC response |
| De-risking Path | 7 | Existing NO donors, calcium modulators in pipeline |

Total: 72/100

Disease Coverage

| Disease | Coverage | Rationale |
|---------|----------|-----------|
| Alzheimer's Disease | 10 | Primary target - NVC impairment documented early |
| Vascular Dementia | 9 | Core mechanism involves CBF dysregulation |
| Aging | 8 | NVC declines with normal aging |
| Parkinson's Disease | 6 | CBF autoregulation impaired in PD |
| FTD | 5 | Some NVC components affected |
| DLB | 5 | Vascular contributions to Lewy body pathology |

Implementation Strategy

Phase 1: Target Identification

Screen for astrocyte calcium modulators (existing FDA drugs)
Develop pericyte-targeted small molecules
Test EET analogs in model systems

Phase 2: Combination Approach

NO donor + astrocyte sensitizer combinations
Pericyte relaxant + anti-amyloid for AD

Phase 3: Biomarker Integration

fMRI NVC response as primary endpoint
ASL (Arterial Spin Labeling) for CBF measurement
Cognitive correlations with NVC improvement

Next Steps

Literature review on existing astrocyte/pericyte modulators

Identify candidate compounds for repurposing

Design biomarker-integrated clinical trial

Partner with neuroimaging groups

References

[Takano et al., Astrocyte-mediated control of cerebral blood flow (2014)](https://pubmed.ncbi.nlm.nih.gov/20098405/)

[Osés et al., Neurovascular coupling dysfunction in Alzheimer's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)

[Zonta et al., Activation of Schaffer collateral commits astrocyte NVC (2003)](https://pubmed.ncbi.nlm.nih.gov/14615434/)

[Attwell et al., Glial and neuronal control of brain blood flow (2010)](https://pubmed.ncbi.nlm.nih.gov/21102956/)

[Iadecola C, The neurovascular unit coming of age (2017)](https://pubmed.ncbi.nlm.nih.gov/28473409/)

[Networks N, Neurovascular dysfunction in dementia (2016)](https://pubmed.ncbi.nlm.nih.gov/27235153/)

[Korte et al., Failing neurovascular coupling in aging (2019)](https://pubmed.ncbi.nlm.nih.gov/31267688/)

[Clementi et al., Pericyte signaling in neurovascular coupling (2018)](https://pubmed.ncbi.nlm.nih.gov/29500342/)

📖 View canonical wiki page →